Practical Insights on How to Improve Comprehensive Biomarker Testing in Advanced Non-Small Cell Lung Cancer

Sign-up for the second in a 6-part series, titled, “Proactive Interventions for the Prior Authorization Process”

Explore opportunities to expand multidisciplinary care collaboration and coordination to improve care for patients with non-melanoma skin cancers.

Raise awareness among cancer programs of new treatment options for newly diagnosed patients with multiple myeloma ineligible for transplant.

Sign-up for the first in a 6-part series, titled, “Proactive Interventions for the Prior Authorization Process”

Oncology state society leaders from the Appalachian Community Cancer Alliance share an introduction to the Alliance, their insights into the unique needs of the Appalachian region and beyond, how the Alliance is responding and how you can get involved.

This educational initiative will focus on multidisciplinary education surrounding TILs, with an emphasis on the importance of implementing clinical trials in the community setting.

This interactive webinar will review how the steps in the life cycle of a patient specimen can affect its molecular integrity and molecular analysis results. Our expert speaker will define the roles of stewardship across the specimen chain of custody, discuss common factors that compromise specimen fitness for molecular testing, and describe solutions to improve preanalytics and tissue stewardship.

Two thought leaders who have deep knowledge of--and experience in--biomarker testing in patients with hematologic malignancies will discuss best practices for biomarker testing in chronic lymphocytic leukemia (CLL) and multiple myeloma based on patient case discussions and the latest guidelines.

Bispecific antibodies are an emerging class of novel immunotherapy agents that have led to major breakthroughs in treating hematologic malignancies—and have promising applications for solid tumors. Learn about the mechanism of bispecific antibodies, discover existing and emerging therapies, and hear about the administration of the first FDA-approved bispecific antibody for the treatment of malignancy, including challenges and opportunities.